Press release
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms LONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) --
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms\nLONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress, which is being held from October 22-25, 2024, in Rome, Italy. The posters are available on the Posters and Publications page of the Company’s website. The details of the poster presentations are as follows: Poster Number: P0015Abstract Title: Evolution of a high-producing, modular upstream platform for AAV manufacturingPoster Session III: Tuesday 22 October from 19:30 to 21:00 CESTAbstract:The poster shows the evolution of MeiraGTx’s upstream manufacturing platform, which was optimized and modulated through the choice of transfection reagents, adeno-associated virus (AAV) production enhancers, and transfection parameters, in fed-batch and perfusion culture mode. Over 3 years, we have achieved process optimizations yielding AAV titers up to 1x1012 VG/mL at harvest and >40% full capsids prior to polishing purification steps. Product quality attributes such as encapsidated residual plasmid DNA and host cell DNA are demonstrated to be controllable and maintained to satisfactory levels for patient safety through the combination of transfection reagent, small molecule enhancer, and transfection mix formulation parameters. Operating a perfusion-based process has also increased volumetric VG yield by approximately 40% and reduced plasmid DNA usage by at least 25%, without compromising on AAV productivity and product quality, demonstrating additional cost savings. Poster Number: P0020Abstract Title: AAV-based evaluation of novel in silico promoters to drive expression in rod photoreceptorsPoster Session II: Wednesday 23 October from 13:30 to 15:00 CESTAbstract:As rods outnumber cones by a ratio of 1:20 or greater in the retina and defects are common in rods leading to various ocular diseases, we sought to design and test novel promoters to drive expression specifically and at high expression levels in rods. Using an AI-assisted promoter engineering approach, ten novel promoter sequences were initially designed, cloned into an adeno-associated virus ...